4:37 PM
Nov 07, 2018
 |  BC Extra  |  Company News

Phase II trial alone may not support BLA for Voyager's Parkinson's gene therapy

Voyager Therapeutics Inc. (NASDAQ:VYGR) said late Wednesday that FDA now considers a randomized Phase II trial of VY-AADC to be an "early phase exploratory study," suggesting that the Phase II trial by itself may no longer be sufficient to support a BLA for the Parkinson's disease gene therapy. The company plans to meet with...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >